Growth-stage biotech companies routinely pass GLP audits and regulatory inspections, yet still experience submission delays, rising consultant costs, and evidence gaps at the moments that matter most.
This white paper examines why audit readiness and operational readiness diverge as clinical programs scale, how evidence reconstruction creates hidden capital risk, and what leading organizations are doing to embed structural readiness before Phase II compression hits.
